A Case Study of Chronic Immune Thrombocytopenia in Children Treated with Hetrombopag
The clinicians and clinical pharmacists developed a treatment regimen and monitoring goals for hetrom-bopog for a child with chronic immune thrombocytopenia,followed by pharmacological care by a clinical pharma-cist.The child's platelets were achieved and maintained in the target range through 20 +weeks of hetrombopog thera-py,and platelets remained in the normal range 14 weeks after discontinuation of the drug.No significant adverse drug reactions were observed during the medication period.It provides a reference for the clinical application practice of hetrombopog in the treatment of chronic immune thrombocytopenia in children.